Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials - Summary - MDSpire
To assess whether baseline atopic dermatitis (AD) severity was associated with short- and long-term abrocitinib efficacy and safety in adults and adolescents.
Approach:
Study design: Post hoc pooled analysis of two phase 3 trials: JADE COMPARE at week 16 and JADE EXTEND through week 112.
Severity groups: Patients were classified as having moderate or severe AD using baseline PtGA, combined EASI/IGA, or body-surface-area criteria; PtGA was excluded from the long-term classification.
Assessments: Efficacy measures included IGA response, EASI-75, EASI-90 with itch score 0/1, and a ≥4-point reduction in peak-pruritus NRS. Abrocitinib was given at 100 or 200 mg once daily, with topical therapy in the short-term trial and with or without topical corticoste…
Key Findings:
The article context reports rapid and sustained improvements in skin clearance and itch across baseline severity subgroups, regardless of the severity-assessment method.
The analysis evaluated week-16 and week-112 outcomes; the provided context does not include numerical response rates or detailed safety results.
Interpretation:
The authors report that abrocitinib responses were observed in patients with moderate or severe baseline AD across the severity definitions examined.
Limitations:
This was a post hoc pooled analysis of randomized trials.
Baseline severity subgroup definitions differed by assessment method; the long-term analysis excluded PtGA.
The supplied context does not provide detailed numerical efficacy or safety results.
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
